[1]吕琛,焦甲勋,杜雪亭,等.免疫检查点抑制剂相关眼部毒性:全球文献病例统计分析[J].眼科新进展,2021,41(5):401-407.[doi:10.13389/j.cnki.rao.2021.0084]
　L Chen,JIAO Jiaxun,DU Xueting,et al.Ocular toxicity associated with immune checkpoint inhibitors: A statistical analysis of literature worldwide[J].Recent Advances in Ophthalmology,2021,41(5):401-407.[doi:10.13389/j.cnki.rao.2021.0084]
点击复制

免疫检查点抑制剂相关眼部毒性:全球文献病例统计分析/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
41卷
期数:
2021年5期
页码:
401-407
栏目:
特别报告
出版日期:
2021-05-05

文章信息/Info

Title:
Ocular toxicity associated with immune checkpoint inhibitors: A statistical analysis of literature worldwide
作者:
吕琛; 焦甲勋; 杜雪亭; 朱小丽
053000　河北省衡水市，衡水市人民医院肿瘤内科（吕琛）；053000　河北省衡水市，衡水市人民医院骨肿瘤科（焦甲勋）；053000　河北省衡水市，衡水市人民医院药学部（杜雪亭，朱小丽）
Author(s):
L Chen1; JIAO Jiaxun2; DU Xueting3; ZHU Xiaoli3
1.Department of Medical Oncology,the People’s Hospital of Hengshui,Hengshui 053000,Hebei Province,China
2.Department of Bone Tumors,the People’s Hospital of Hengshui,Hengshui 053000,Hebei Province,China
3.Department of Pharmacy,the People’s Hospital of Hengshui,Hengshui 053000,Hebei Province,China
关键词:
免疫检查点抑制剂; 细胞毒性 T 淋巴细胞相关抗原-4; 程序性死亡受体-1; 程序性死亡配体-1; 眼毒性
Keywords:
immune checkpoint inhibitors;  cytotoxic T lymphocyte-associated antigen 4;  programmed cell death protein 1;  programmed death-ligand 1;  ocular toxicity
分类号:
R771.3
DOI:
10.13389/j.cnki.rao.2021.0084
文献标志码:
A
摘要:
免疫检查点抑制剂通过抑制细胞毒性T淋巴细胞相关抗原-4、程序性死亡受体-1、程序性死亡配体-1阻断肿瘤的免疫逃逸途径，从而达到杀伤肿瘤细胞的目的。然而，免疫系统的激活也会引起免疫相关的不良反应。尽管免疫检查点抑制剂所导致的眼部毒性并不常见，但是能够涉及到眼部所有组织，可能影响部分患者的免疫检查点抑制剂的使用疗程。本文通过文献检索的方法收集免疫检查点抑制剂导致眼部毒性的病例，对患者的性别、年龄、原患疾病、用药情况、临床症状、发生时间、治疗方法及转归等进行汇总分析，以期提高医务人员对免疫检查点抑制剂相关眼部毒性的认识。
Abstract:
Immune checkpoint inhibitors (ICIs) block the immune escape pathway by inhibiting cytotoxic T lymphocyte-associated antigen 4, programmed death receptor-1 and programmed death-ligand 1, thus killing the tumor. However, the activation of immune system can also cause the immune-related adverse event. Although the ocular toxicity caused by ICIs is uncommon, all ocular tissues can be involved. As a result, the course of treatment with ICIs may be affected in some patients. In this article, the cases with ocular toxicity caused by ICIs were collected by literature research, and the gender, age, original diseases, medications, clinical symptoms, occurrence time, treatment methods and outcomes were analyzed to improve the medial personnel’s understanding of ICIs related ocular toxicity.

参考文献/References:

［1］　ABDEL-RAHMAN O,ELHALAWANI H,FOUAD M.Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors:a meta-analysis ［J］.Future Oncol,2015,11(17):2471-2484.
［2］　ABDEL-RAHMAN O,ELHALAWANI H,FOUAD M.Risk of elevated transaminases in cancer patients treated with immune checkpoint inhibitors:a meta-analysis ［J］.Expert Opin Drug Saf,2015,4(10):1507-1518.
［3］　ABDEL-RAHMAN O,ELHALAWANI H,FOUAD M.Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors:a meta-analysis ［J］.Immunotherapy,2015,7(11):1213-1227.
［4］　ABDEL-RAHMAN O,FOUAD M.Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors:a meta-analysis ［J］.Ther Adv Respir Dis,2016,10(3):183-193.
［5］　ABDEL-RAHMAN O,FOUAD M.A network meta-analysis of the risk of immune-related renal toxicity in cancer patients treated with immune checkpoint inhibitors ［J］.Immunotherapy,2016,8(5):665-674.
［6］　ABDEL-RAHMAN O,HELBLING D,SCHMIDT J,PETRAUSCH U,GIRYES A,MEHRABI A,et al.Treatment-associated fatigue in cancer patients treated with immune checkpoint inhibitors:a systematic review and meta-analysis［J］.Clin Oncol,2016,28(10):e127-138.
［7］　TARHINI A.Immune-mediated adverse events associated with ipilimumab CTLA-4 blockade therapy:the underlying mechanisms and clinical management ［J］.Scientifica,2013,20(13):857519.
［8］　SEIDEL J A,OTSUKA A,KABASHIMA K.Anti-PD-1 and anti-CTLA-4 therapies in cancer:mechanisms of action,efficacy,and limitations［J］.Front Oncol,2018,28(8):86.
［9］　TOPALIAN S L,HODI F S,BRAHMER J R,GETTINGER S N,SMITH D C,MCDERMOTT D F,et al.Safety,activity and immune correlates of anti-PD-1 antibody in cancer ［J］.N Engl J Med,2012,366(26):2443-2454.
［10］　BRAHMER J R,TYKODI S S,CHOW L Q,HWU W J,TOPALIAN S L,HWU P,et al.Safety and activity of anti-PD-L1 antibody in patients with advanced cancer ［J］.N Engl J Med,2012,366(26):2455-2465.
［11］　LARKIN J,HODI F S,WOLCHOK J D.Combined nivolumab and ipilimumab or monotherapy in untreated melanoma ［J］.N Engl J Med,2015,373(13):1270-1271.
［12］　谢同济,王守正,邢镨元.解析PD-1/PD-L1抑制剂分子结构差异与不良反应的相关性［J］.中国肺癌杂志,2020,23(7):603-608.
XIE T J,WANG S Z,XING P Y.Analysis of the correlation between molecular structural differences of PD-1/PD-L1 inhibitors and adverse events ［J］.Chin J Lung Cancer,2020,23(7):603-608.
［13］　XU C,CHEN Y P,DU X J,LIU J Q,HUANG C L,CHEN L,et al.Comparative safety of immune checkpoint inhibitors in cancer:systematic review and network meta-analysis ［J］.BMJ,2018,363(8):k4226.
［14］　LIN L L,LIN G F,LUO Q,CHEN X Q.The incidence and relative risk of PD-1/PD-L1 inhibitors-related colitis in non-small cell lung cancer:a metaanalysis of randomized controlled trials ［J］.Int Immunopharmacol,2019,77:105975.
［15］　PILLAI R N,BEHERA M,OWONIKOKO T K,KAMPHORST A O,PAKKALA S.Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer:a systematic analysis of the literature ［J］.Cancer,2018,124(2):271-277.
［16］　KHUNGER M,RAKSHIT S,PASUPULETI V,HERNANDEZ A V,MAZZONE P,BELANI C P,et al.Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer:a systematic review and meta-analysis of trials ［J］.Chest,2017,152(2):271-281.
［17］　DELLA VITTORIA SCARPATI G,FUSCIELLO C,PERRI F,SABBATINO F,FERRONE S,CARLOMAGNO C,et al.Ipilimumab in the treatment ofmetastatic melanoma:management of adverse events ［J］.Onco Targets Ther,2014,19(7):203-209.
［18］　ZIMMER L,GOLDINGER S M,HOFMANN L,LOQUAI C,UGUREL S,THOMAS I,et al.Neurological,respiratory,musculoskeletal,cardiac and ocular side-effects of anti-PD-1 therapy ［J］.Eur J Cancer,2016,60(13):210-225.
［19］　SUN M M,LEVINSON R,FILIPOWICZ A D O,ANESI S,KAPLAN H,WANG W,et al.Uveitis in patients treated with CTLA-4 and PD-1 checkpoint blockade inhibition ［J］.Ocul Immunol Inflamm,2020,28(2):217-227.
［20］　MUHAMMAD F,WANG D,MONTIETH A,LEE S,PREBLE J,FOSTER C S,et al.PD-1＋ melanocortin receptor dependent-Treg cells prevent autoimmune disease ［J］.Sci Rep,2019,9(1):16941.
［21］　MENG Q L,YANG P Z,GUO H K,ZHANG L,CHEN X,JIANG Z X,et al.Characteristic expression of PD-1 and its ligands mRNAs in patients with noninfectious uveitis ［J］.Int J Clin Exp Med,2016,9(1):323-329.
［22］　SHIELDS C L,SAY E A T,MASHAYEKHI A,GARG S J,DUNN J P,SHIELDS J A.Assessment of CTLA-4 deficiency-related autoimmune choroidopathy response to abatacept［J］.JAMA Ophthalmol,2016,134(7):844-846.
［23］　EL A J,GOYAL S,ZHANG Q,FREEMAN G J,SHARPE A H,DANA R.Regulation of T-cell chemotaxis by programmed death-ligand 1(PD-L1) in dry eye-associated corneal inflammation［J］.Invest Ophthalmol Vis Sci,2010,51(7):3418-3423.
［24］　BITTON K,MICHOT J,BARREAU E,LAMBOTTE O,HAIGH O,MARABELLE A,et al.Prevalence and clinical patterns of ocular complications associated with anti-PD-1/PD-L1 anticancer immunotherapy ［J］.Am J Ophthalmol,2019,202:109-117.
［25］　WITMER M T.Treatment of ipilimumab-induced vogt-koyanagi-harada syndrome with oral dexamethasone ［J］.Ophthalmic Surg Lasers Imaging Retina,2017,48(11):928-931.
［26］　WEGNER A,KHORAMNIA R.Neurosensory retinal detachment due to sunitinibtreatment［J］.Eye,2011,25(11):1517-1518.
［27］　OPPONG E,CATO A C.Effects of glucocorticoids in the immune system ［J］.Adv Exp Med Biol,2015,872:217-233.
［28］　KIM H D,PARK S H.Immunological and clinical implications ofimmune checkpoint blockade in human cancer ［J］.Arch Pharm Res,2019,42(7):567-581.
［29］　DONG H,STROME S E,SALOMAO D R,TAMURA H,HIRANO F,FLIES D B,et al.Tumor-associated B7-H1 promotes T-cell apoptosis:a potential mechanism of immune evasion ［J］.Nat Med,2002,8(8):793-800.
［30］　RICCIUTI B,DAHLBERG S E,ADENI A,SHOLL L M,NISHINO M,AWAD M M.Immune checkpoint inhibitor outcomes for patients with non-small-cell lung cancer receiving baseline corticosteroids for palliative versus nonpalliative indications ［J］.J Clin Oncol,2019,37(22):1927-1934.
［31］　HORVAT T Z,ADEL N G,DANG T O,MOMTAZ P,POSTOW M A,CALLAHAN M K,et al.Immune-related adverse events,need for systemic immunosuppression,and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial sloan kettering cancer center ［J］.J Clin Oncol,2015,33(28):3193-3198.
［32］　WEBER J S,HODI F S,WOLCHOK J D,TOPALIAN S L,SCHADENDORF D,LARKIN J,et al.Safety profile of nivolumab monotherapy:a pooled analysis of patients with advanced melanoma ［J］.J Clin Oncol,2017,35(7):785-792.
［33］　SHAFQAT H J,GOURDIN L,SION A.Immune-related adverse events are linked with improved progression-free survival in patients receiving anti-PD-1/PD-L1 therapy ［J］.Semin Oncol,2018,45(3):156-163.
［34］　ARBOUR K C,MEZQUITA L,LONG N,RIZVI H,AUCLIN E,NI A,et al．Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer［J］.J Clin Oncol,2018,36(28):2872-2878.
［35］　HENDRIKS L E L,HENON C,AUCLIN E,MEZQUITA L,FERRARA R,AUDIGIER-VALETTE C,et al.Outcome of patients with non-small-cell lung cancer and brain metastases treated with checkpoint inhibitors ［J］.J Thorac Oncol,2019,14(7):1244-1254.
［36］　RICCIUTI B,DHLBERG S E,ADENI A,SHOLL L M,NISHINO M,AWAD M M.Immune checkpoint inhibitor outcomes for patients with non-small-cell lung cancer receiving baseline corticosteroids for palliative versus nonpalliative indications ［J］.J Clin Oncol,2019,37(22):1927-1934.
［37］　LANGER C J,GADGEEL S M,BORGHAEI H,PAPADIMITRAKOPOULOU V A,PATNAIK A,POWELL S F,et al.Carboplatin and pemetrexed with or without pembrolizumab for advanced,non-squamous non-small-cell lung cancer:a randomised,phase 2 cohort of the open-label KEYNOTE-021 study ［J］.Lancet Oncol,2016,17(11):1497-1508.
［38］　SOCINSKI M A,JOTTE R M,CAPPUZZO F,ORLANDI F,STROYAKOVSKIY D,NOGAMI N,et al.Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC ［J］.N Engl J Med,2018,378(24):2288-2301.
［39］　PAZ-ARES L,LUFT A,VICENTE D,TAFRESHI A,GUMUS M,MAZIERES J,et al.Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer［J］.N Engl J Med,2018,379(21):2040-2051.
［40］　GANDHI L,RODRIGUEZ-ABREU D,GADGEEL S,ESTEBAN E,FELIP E,DE ANGELIS F,et al.Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer ［J］.N Engl J Med,2018,378(22):2078-2092.
［41］　SHAFQAT H,GOURDIN L,SION A.Immune-related adverse events are linked with improved progression-free survival in patients receiving anti-PD-1/PD-L1 therapy ［J］.Semin Oncol,2018,45(3):156-163.
［42］　GILES A J,HUTCHINSON M N D,SONNEMANN H M,JUNG J,FECCI P E,RATNAM N M,et al.Dexamethasone-induced immunosuppression:mechanisms and implications for immunotherapy ［J］.J Immunother Cancer,2018,6(1):51.
［43］　FREEMAN-KELLER M,KIM Y,CRONIN H,RICHARDS A,GIBNEY G,WEBER J S.Nivolumab in resected and unresectable metastatic melanoma:characteristics of immune -related adverse events and association with outcomes ［J］.Clin Cancer Res,2016,22(4):886-894.
［44］　FUJII T,COLEN R R,BILEN M A,HESS K R,HAJJAR J,SUAREA-ALMAZOR M E,et al.Incidence of immune-related adverse events and its association with treatment outcomes:the MD anderson cancer center experience ［J］.Invest New Drugs,2018,36(4):638-646.

相似文献/References:

[1]孟倩丽,吕正.PD-1信号通路和CTLA-4在眼科领域的研究进展[J].眼科新进展,2021,41(1):001.[doi:10.13389/j.cnki.rao.2021.0001]
　MENG Qianli,L Zheng.Advance of PD-1 signaling pathways and CTLA-4 in ophthalmology[J].Recent Advances in Ophthalmology,2021,41(5):001.[doi:10.13389/j.cnki.rao.2021.0001]
[2]王润泽,王建文.视网膜母细胞瘤免疫治疗研究进展[J].眼科新进展,2021,41(9):883.[doi:10.13389/j.cnki.rao.2021.0185]
　WANG Runze,WANG Jianwen.Progress in immunotherapy of retinoblastoma[J].Recent Advances in Ophthalmology,2021,41(5):883.[doi:10.13389/j.cnki.rao.2021.0185]
[3]朱笑莹,毕徐齐,李丽红,等.抗PD-1/PD-L1单抗导致药物源性葡萄膜炎的研究进展[J].眼科新进展,2022,42(12):1004.[doi:10.13389/j.cnki.rao.2022.0205]
　ZHU Xiaoying,BI Xuqi,LI Lihong,et al.Research progress of drug-induced uveitis caused by anti-programmed cell death receptor-1/programmed cell death ligand-1 monoclonal antibodies[J].Recent Advances in Ophthalmology,2022,42(5):1004.[doi:10.13389/j.cnki.rao.2022.0205]

备注/Memo

备注/Memo:
N/A
更新日期/Last Update: 2021-05-05